Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 64 Sidney St CAMBRIDGE MA 02139-4170 |
Tel: | N/A |
Website: | https://vcel.com |
IR: | See website |
Key People | ||
Dominick C. Colangelo President, Chief Executive Officer, Director | Joseph A. Mara Chief Financial Officer | Michael Halpin Chief Operating Officer |
Sean C. Flynn Senior Vice President, General Counsel, Secretary | Jonathan Mark Hopper Chief Medical Officer |
Business Overview |
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. |
Financial Overview |
For the three months ended 31 March 2024, Vericel Corp revenues increased 25% to $51.3M. Net loss decreased 48% to $3.9M. Revenues reflect MACI segment increase of 18% to $40.2M, Epicel segment increase of 56% to $10.7M. Lower net loss reflects Interest Income increase from $839K to $1.8M (income), Other expense decrease of 42% to $7K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.16 to -$0.08. |
Employees: | 314 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,227M as of Mar 31, 2024 |
Annual revenue (TTM): | $207.78M as of Mar 31, 2024 |
EBITDA (TTM): | $1.20M as of Mar 31, 2024 |
Net annual income (TTM): | $0.45M as of Mar 31, 2024 |
Free cash flow (TTM): | $2.04M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 48,601,736 as of Apr 30, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |